Alexandria, VA (February 28, 2018) - The Pharmacy Quality Alliance (PQA), VUCA Health LLC, and Liberty Software, Inc. are pleased to announce a research partnership to assess the impact of patient educational videos on improving primary medication nonadherence (PMN).
Primary medication nonadherence occurs when a new medication is prescribed for a patient, however, the patient does not obtain the medication, or appropriate alternative, within an acceptable period of time after it was prescribed. It is estimated that rates of PMN can range from 15% to as high as 30% for various chronic medications. PQA, in collaboration with VUCA Health, a patient engagement health technology company, and Liberty Software, a pharmacy software company, will address this issue by creating an automatic pushed message to the patient on behalf of the pharmacy. The message will be sent via SMS text or email upon receipt of a new electronic prescription and will include a web link to an educational video briefing about the medication and additional digital medication information.
"The increased growth of electronic prescribing has enabled providers and researchers to more precisely investigate interventions that target PMN," said Laura Cranston, CEO of PQA. "PQA is very excited to partner with VUCA Health and Liberty Software to explore a scalable solution for improving PMN."
According to David Medvedeff, CEO of VUCA Health, "Quality measurement is the foundation to a more patient-centered and value-driven healthcare system. It is a privilege to partner with the preeminent pharmacy quality measurement organization [PQA] in demonstrating how a validated measure can improve patient outcomes. We look forward to empowering patients with leading edge content to support their therapeutic goals."
Jeremy Manchester, Executive Vice President of Liberty Software shared, "Addressing primary medication nonadherence is a top priority for the pharmacy profession and our organization. Utilizing our platform to provide tools to help pharmacists improve patient adherence and providing them the functionality to tackle PMN is exciting and we are optimistic about what this research initiative may demonstrate. VUCA Health and PQA are innovative organizations and we are excited to partner with them to improve patient care."
This 12-month project will kick off during the first quarter of 2018 in several independent pharmacies across the Southeast region of the United States, including Texas in the Southwest. Support for this activity was provided through an independent educational grant from Merck Sharp & Dohme Corp.